Treatment Costs and Social Burden of Pancreatic Cancer
Cancers · 22.03.2023 · 15 (6) · 1911
DOI: 10.3390/cancers15061911 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.03.2023. Verfasst von Elżbieta Cipora und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical Institute, Jan Grodek State University in Sanok, 38-500 Sanok, Poland. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
Pancreatic cancer is the cancer with the third-highest mortality rate, and forecasts indicate its growing share in morbidity. The basis of treatment is inpatient chemotherapy and there is a strong focus on palliative care. (2)
Methods
A literature review was conducted based on the rapid review methodology in PubMed and Cochrane databases. The search was supplemented with publications from the snowball search. Qualitative assessment of included publications was performed using AMSTAR2 modified scheme. (3)
Results
The review included 17 publications, of which majority concerned direct costs related to the adopted treatment regimen. Most of the publications focused on comparing the cost-effectiveness of drug therapies and the costs of palliative treatment. Other publications concerned indirect costs generated by pancreatic cancer. They particularly focused on the economic burden of lost productivity due to sickness absence. (4)
Conclusion
The increase in the incidence of pancreatic cancer translates into an increase in the costs of the health care system and indirect costs. Due to the significant share of hospitalization in the health care structure, direct costs are increasing. The inpatient treatment regimen and side effects translate into a loss of productivity for patients with pancreatic cancer. Among gastrointestinal cancers, pancreatic cancer generates the second largest indirect costs, although it has a much lower incidence rate than the dominant colorectal cancer. This indicates a significant problem of the economic burden of this cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Institute, Jan Grodek State University in Sanok, 38-500 Sanok, Poland.
- Department of Economic and System Analyses, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.
- Department of Health Economics and Medical Law, Medical University of Warsaw, 01-445 Warsaw, Poland.
- Faculty of Health Sciences, Calisia University, 62-800 Kalisz, Poland.
- Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
- Department of Basic of Nursing, Faculty of Health Sciences, Medical University of Warsaw, 01-445 Warsaw, Poland.
ORCID-Profile: Elżbieta Cipora, Olga Partyka, Monika Pajewska, Aleksandra Czerw, Katarzyna Sygit, Mateusz Kaczmarski, Anna Jurczak, Sylwia Wieder-Huszla, Tomasz Banaś, Weronika Ciećko, Andrzej Deptała
Zitieren
APA
Cipora, E., Partyka, O., Pajewska, M., Czerw, A., Sygit, K., Sygit, M., Kaczmarski, M., Mękal, D., Krzych-Fałta, E., Jurczak, A., Karakiewicz-Krawczyk, K., Wieder-Huszla, S., Banaś, T., Bandurska, E., Ciećko, W., & Deptała, A. (2023). Treatment Costs and Social Burden of Pancreatic Cancer. Cancers, 15(6), 1911. https://doi.org/10.3390/cancers15061911
Vancouver
Cipora E, Partyka O, Pajewska M, Czerw A, Sygit K, Sygit M, et al. Treatment Costs and Social Burden of Pancreatic Cancer. Cancers. 2023;15(6):1911. doi:10.3390/cancers15061911
BibTeX
@article{Cipora2023,
author = {Cipora, Elżbieta and Partyka, Olga and Pajewska, Monika and Czerw, Aleksandra and Sygit, Katarzyna and Sygit, Marian and Kaczmarski, Mateusz and Mękal, Dominika and Krzych-Fałta, Edyta and Jurczak, Anna and Karakiewicz-Krawczyk, Katarzyna and Wieder-Huszla, Sylwia and Banaś, Tomasz and Bandurska, Ewa and Ciećko, Weronika and Deptała, Andrzej},
title = {Treatment Costs and Social Burden of Pancreatic Cancer},
journal = {Cancers},
year = {2023},
volume = {15},
number = {6},
pages = {1911},
doi = {10.3390/cancers15061911}
}
EUVIMED